Roche

Swiss multinational pharmaceutical and diagnostics company specializing in oncology, immunology, infectious diseases, and personalized healthcare solutions.

Company Type

public

Founded

1896

Headquarters

Basel, Switzerland

Stock

SIX: ROG

Revenue

CHF 61.5 billion (FY2025)

Employees

Approximately 101,000

Primary Market

Global

science based targetssustainable manufacturingenvironmental initiatives

About Roche

Roche operates through two main business divisions: Pharmaceuticals and Diagnostics, creating a unique integrated healthcare company that combines treatment and diagnostic capabilities. This dual focus enables Roche to deliver personalized healthcare solutions, matching patients with the most effective treatments based on diagnostic information and molecular characteristics.

The Pharmaceuticals division develops and manufactures prescription medicines across multiple therapeutic areas, with particular strength in oncology, immunology, neuroscience, infectious diseases, and rare diseases. Roche's pharmaceutical portfolio includes both established blockbuster products and innovative new treatments that address significant unmet medical needs. The division maintains a global research and development network with facilities across multiple continents, investing billions annually in pharmaceutical innovation, clinical trials, and regulatory approvals.

The Diagnostics division produces laboratory testing systems, molecular diagnostics, and point-of-care testing devices that support healthcare professionals in disease detection, monitoring, and treatment selection. Roche's diagnostic capabilities include automated laboratory systems, molecular testing platforms, and digital health solutions. The division's integrated approach with pharmaceuticals creates unique advantages in personalized medicine, enabling precise treatment selection based on diagnostic information.

Roche's business philosophy emphasizes innovation, patient-centricity, and sustainable value creation. The company maintains a strong focus on research and development, with approximately 20% of pharmaceutical revenues invested in R&D activities. This investment supports a robust pipeline of new treatments and diagnostic solutions, with 10 key molecules advancing into phase III development in 2025 alone.

Financial performance in 2025 demonstrated the strength of Roche's integrated business model. The company reported 7% sales growth at constant exchange rates to CHF 61.5 billion, with the Pharmaceuticals Division achieving 9% growth and the Diagnostics Division growing 2%. Core operating profit increased by 13%, reflecting operational efficiency and strong demand for both pharmaceutical and diagnostic solutions.

Key growth drivers in 2025 included Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. These products demonstrate Roche's strength across multiple therapeutic areas and its ability to deliver innovative treatments that address significant patient needs.

Looking toward 2026, Roche expects Group sales growth in the mid single digit range and core earnings per share growth in the high single digit range at constant exchange rates. The company plans to further increase its dividend to CHF 9.80 per share, which would mark the 39th consecutive dividend increase if approved by shareholders. For 2026, Roche is shifting focus from consolidation to optimization, emphasizing internal pipeline development and R&D process improvements to enhance productivity and decision-making.

Roche's strategic priorities include investing in programs with potential to redefine care standards, particularly in oncology, neuroscience, and immunology. The company maintains a $10 billion annual budget for potential acquisitions and partnerships, prioritizing strategic fit and scientific differentiation over transaction size. This approach reflects Roche's commitment to long-term value creation and sustainable growth while maintaining operational discipline.

Visit official website

History of Roche

Roche was founded in 1896 by Fritz Hoffmann-Oeri in Basel, Switzerland, establishing the company as "F. Hoffmann-La Roche & Co." The founder's vision was to create innovative pharmaceutical solutions that would serve patients globally, building on the emerging field of industrial pharmaceutical manufacturing. Fritz Hoffmann-Oeri's approach combined scientific rigor with business acumen, establishing principles that continue to guide the company today.

Throughout the early 20th century, Roche expanded its product portfolio and became known for its commitment to pharmaceutical innovation and quality. The company established itself as one of Switzerland's leading pharmaceutical manufacturers, with products serving diverse therapeutic areas including vitamins, hormones, and antibiotics. Roche became a trusted brand among healthcare professionals and patients, building a reputation for reliability and scientific excellence.

The mid-20th century marked significant expansion for Roche, particularly through strategic acquisitions and international growth. In 1964, Roche acquired a majority stake in Genentech, establishing a foundation for future biotechnology leadership. The company expanded into diagnostics, becoming a leader in laboratory testing and diagnostic solutions through acquisitions like Boehringer Mannheim in 1997. Roche established itself as a leader in oncology, immunology, and infectious diseases through both internal development and strategic acquisitions.

The 1990s and early 2000s represented a period of transformation for Roche, with major investments in biotechnology and personalized medicine. The company strengthened its position in oncology with breakthrough treatments like Herceptin (trastuzumab) for breast cancer and Rituxan (rituximab) for non-Hodgkin lymphoma. These innovations established Roche as a leader in targeted cancer therapies and personalized medicine approaches.

In recent decades, Roche has continued to focus on innovation in pharmaceuticals and diagnostics, investing heavily in molecular diagnostics, precision medicine, and digital health solutions. The company has maintained its leadership position in oncology while expanding into neuroscience, immunology, and rare diseases. Roche's integrated approach combining pharmaceuticals and diagnostics has created unique capabilities in personalized healthcare.

The year 2025 marked another strong performance year for Roche, with the company reporting 7% sales growth at constant exchange rates to CHF 61.5 billion. The Pharmaceuticals Division achieved 9% growth, driven by strong performance of key products including Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. The Diagnostics Division grew 2%, demonstrating resilience despite healthcare pricing reforms in China.

Roche's 2025 achievements included significant regulatory approvals and clinical development milestones. The company received US and EU approval for the subcutaneous form of Lunsumio for blood cancer and EU approval for Gazyva/Gazyvaro for lupus nephritis. Roche advanced 10 key molecules into phase III development and received EU CE marks for innovative diagnostic tests including the Elecsys Dengue Ag test and cobas BV/CV assay. These achievements demonstrate Roche's continued commitment to innovation and its ability to deliver new treatments and diagnostic solutions to patients worldwide.

Roche Sustainability & Ethics

Roche has committed to achieving net zero carbon emissions by 2045 and has set near-term and long-term targets validated by the Science Based Targets initiative in 2025. The company's climate strategy includes reducing absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030 against a 2019 baseline. In 2024, Roche reduced Scope 1 and 2 emissions by approximately 40% against the 2019 baseline, ahead of its 2025 interim target.

The company has committed to increasing sustainable electricity to 100% by 2025 and has made substantial progress toward this goal. Roche sources renewable electricity for a significant portion of its global manufacturing operations and has invested in energy efficiency programs across production facilities. The company participates in the Energize programme, which aims to increase access to renewable energy electricity for suppliers to the pharmaceutical industry.

Roche is a founding member of the Biopharma Sustainability Roundtable (established 2013) and has been a member of the World Business Council for Sustainable Development since 1995, participating actively in Circular Plastics & Packaging and Partnership for Carbon Transparency projects. The company joined the Sustainable Markets Initiative in 2021 as a founding member and actively participates in the Health Systems Industry Taskforce.

The company has set targets to halve the environmental impact of its operations and products from a 2019 baseline by 2029. Water consumption reduction targets include a 15% decrease by 2025 from a 2020 baseline, with nutrient discharge reductions of 5% for nitrogen and 90% for phosphorus. Waste management goals include reducing general waste by 10% and achieving an 80% recycling rate for general waste by 2025.

Roche is not a Certified B Corporation, and the company does not hold cruelty-free certification from Leaping Bunny or PETA at the group level, as pharmaceutical companies are required to conduct animal testing for regulatory approval in most jurisdictions. The company states it is pioneering and promoting innovative approaches in preclinical research to replace animal testing where scientifically and ethically appropriate.

In 2025, Roche received a Silver medal from EcoVadis sustainability rating agency, achieving a score of 69 out of 100, placing the company in the top 15% of companies rated. In 2024, Roche ranked 11th out of 20 of the world's biggest pharmaceutical companies assessed by the Access to Medicine Index.

Roche publishes an annual Sustainability Report with independently assured performance data and maintains extensive ESG disclosure through its investor relations materials. The company's sustainability governance is integrated into its business strategy, with commitment from senior management reflected in the sustainability governance structure.

Awards & Recognition

Roche has received consistent recognition for innovation, research capability, and workplace practices from independent rating organizations and industry bodies.

In 2026, Roche and its subsidiary Genentech were both recognized on Glassdoor's Best Places to Work list in the United States, reflecting employee satisfaction and workplace culture. The company was named one of the world's top 10 BioPharma employers in the Science Magazine 2025 list, demonstrating its reputation as an employer of choice in the life sciences sector.

Roche has been included in Fortune's World's Most Admired Companies ranking, reflecting peer and analyst respect for the company's operational capabilities and market position. The company maintains a presence in major ESG indices, including the Dow Jones Sustainability Index North America, assessed annually by S&P Global for ESG performance among large cap companies.

The company's innovation capabilities have been recognized through its consistent inclusion in pharmaceutical industry innovation rankings. Roche's R&D productivity, measured by the number of new molecular entities in development and regulatory approvals achieved, places it among the most innovative pharmaceutical companies globally.

Roche's 39 consecutive years of dividend increases, pending shareholder approval for 2026, demonstrates financial stability and commitment to shareholder returns. This track record places Roche among a select group of companies with multi-decade dividend growth histories.

Controversy, Regulation & Public Scrutiny

Roche has faced regulatory and legal challenges typical of large pharmaceutical companies operating in highly regulated markets globally.

In October 2025, Roche suffered a setback when India's Supreme Court allowed generic versions of Evrysdi (risdiplam) for spinal muscular atrophy to be manufactured and sold in India. The court's decision provided an important victory to patient advocates who argue drug makers tweak patents to extend exclusivity. This ruling reflects ongoing tensions between pharmaceutical intellectual property protection and access to medicines in emerging markets.

In March 2026, Russia's Biocad faced potential market loss for cancer drug pertuzumab due to a dispute with Roche over biosimilar development and patent rights. The dispute highlights the complex intellectual property landscape surrounding biologic medicines and biosimilar competition.

Roche has been involved in industry disputes with competitors. In a notable case, Bayer was found to have discredited the pharmaceutical industry after a dispute with Roche, with Bayer claiming that Roche made false and disparaging allegations of deliberate document falsification during business negotiations. The case was adjudicated by industry regulatory bodies.

Like other major pharmaceutical companies, Roche faces ongoing scrutiny regarding drug pricing, particularly in the United States and Europe. The company's pricing strategies for oncology and rare disease treatments have been subject to public debate and regulatory review, though no major pricing-related fines or settlements have been reported in recent years.

Roche's diagnostics business has faced challenges related to healthcare pricing reforms in China, which impacted the division's 2025 performance with a 12% sales decrease in the Asia-Pacific region. These reforms reflect broader government efforts to control healthcare costs and improve access to diagnostic services.

The company maintains transparency regarding legal proceedings through its annual Finance Report, which provides an overview of significant legal cases. As of the 2025 Finance Report, no material litigation beyond ordinary course business disputes was disclosed.

Brands Owned by Roche

Roche owns 4 brands in our database.

Accutane

Owned by Roche

Prescription dermatology medication containing isotretinoin for treating severe acne, originally developed by Roche. The brand-name Accutane was discontinued in the U.S. in 2009, though generic isotretinoin remains widely available.

dermatologyacne-treatmentsevere-acne

Activase

Owned by Roche

Prescription thrombolytic medication for treating acute myocardial infarction and stroke, manufactured and marketed by Roche.

cardiovascularthrombolyticheart-attack

CellCept

Owned by Roche

Prescription immunosuppressant medication for preventing organ rejection in transplant recipients, manufactured and marketed by Roche.

immunosuppressiontransplantorgan-rejection

Tirosint

Owned by Roche

IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.

levothyroxinehypothyroidismthyroid

Shop Roche Brands

Disclosure: We may earn commission from purchases

Accutane on Amazon

Activase on Amazon

CellCept on Amazon

Stock Information

Roche Ownership: Pros & Cons

Advantages

+Global leadership position in oncology with established blockbuster drugs and innovative pipeline
+Integrated pharmaceuticals and diagnostics business model enabling personalized medicine approaches
+Strong financial performance with 7% sales growth in 2025 and consistent dividend increases
+Robust R&D pipeline with 10 key molecules advancing to phase III development in 2025
+Swiss corporate heritage emphasizing quality, precision, and long-term strategic thinking
+Global manufacturing and distribution network ensuring market access and operational efficiency
+Strong regulatory approval track record with major health authorities worldwide
+Significant investment in digital health and molecular diagnostics capabilities
+Financial stability allowing long-term R&D investments without external funding pressure
+Established brand recognition and trust among healthcare professionals and patients

Considerations

-Patent expirations on major oncology drugs creating revenue pressure and generic competition
-Healthcare pricing reforms and cost containment measures affecting reimbursement and pricing
-Intense competition from other pharmaceutical companies in oncology and immunology
-High R&D costs and lengthy clinical development timelines for new treatments
-Regulatory challenges and increasing requirements for clinical trial evidence
-Currency exchange rate fluctuations affecting international revenue reporting
-Dependence on key products for significant revenue concentration
-Complex global supply chain requiring quality control and regulatory compliance
-Need for continuous innovation to maintain market leadership in rapidly evolving therapeutic areas
-Ethical considerations and public scrutiny surrounding pharmaceutical pricing and access

Frequently Asked Questions About Roche

Is Roche owned by another company?

No, Roche is an independent, publicly traded Swiss multinational pharmaceutical and diagnostics company. The company operates without any parent company or controlling shareholder, maintaining complete operational independence since its founding in 1896.

Is Roche publicly traded?

Yes, Roche is publicly traded on the SIX Swiss Exchange under ticker symbol ROG. The company is owned by institutional investors, mutual funds, pension funds, and individual shareholders worldwide, with no controlling shareholder.

When was Roche founded?

Roche was founded in 1896 by Fritz Hoffmann-Oeri in Basel, Switzerland. The company has over 125 years of history in pharmaceutical innovation and has grown from a small Swiss manufacturer into a global healthcare leader.

Who founded Roche?

Roche was founded by Fritz Hoffmann-Oeri, who established the company as "F. Hoffmann-La Roche & Co." with a vision to create innovative pharmaceutical solutions that would serve patients globally. The founding Hoffmann-Oeri family maintains a connection to the company through family foundations and holdings.

What is Roche's market position?

Roche holds a leading position in the global pharmaceutical industry, particularly in oncology where it is the market leader. The company is also a major player in diagnostics, immunology, and neuroscience. In 2025, Roche reported CHF 61.5 billion in sales with 7% growth, demonstrating its strong market position.

What are Roche's main business divisions?

Roche operates through two main divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division develops prescription medicines for oncology, immunology, neuroscience, and other therapeutic areas. The Diagnostics division produces laboratory testing systems, molecular diagnostics, and point-of-care testing devices.

What were Roche's 2025 financial results?

In 2025, Roche achieved CHF 61.5 billion in sales with 7% growth at constant exchange rates. The Pharmaceuticals Division grew 9% while Diagnostics grew 2%. Core operating profit increased by 13%, and the company proposed increasing its dividend to CHF 9.80 per share.

What are Roche's key products?

Roche's key products include Herceptin, Avastin, and Rituxan in oncology; Ocrevus for multiple sclerosis; Xolair for allergic diseases; Hemlibra for hemophilia; and Vabysmo for eye diseases. The company also has diagnostic products and recently approved Lunsumio for blood cancer treatment.

What is Roche's R&D strategy?

Roche invests approximately 20% of pharmaceutical revenues in research and development, focusing on programs with potential to redefine care standards. In 2025, the company advanced 10 key molecules into phase III development and maintains a $10 billion annual budget for potential acquisitions and partnerships.

Where does Roche operate globally?

Roche operates globally with manufacturing locations in Switzerland, United States, Germany, France, Japan, China, India, and Brazil. The company serves patients worldwide through its integrated pharmaceutical and diagnostics business model, with significant commercial operations across North America, Europe, and Asia Pacific.

Is Roche committed to sustainability?

Yes, Roche has committed to achieving net zero carbon emissions by 2045 with targets validated by the Science Based Targets initiative in 2025. The company reduced Scope 1 and 2 emissions by approximately 40% against its 2019 baseline by 2024, ahead of its 2025 interim target. Roche is a founding member of the Biopharma Sustainability Roundtable and received a Silver medal from EcoVadis in 2025.

About Roche

History of Roche

Roche Sustainability & Ethics

Awards & Recognition

Controversy, Regulation & Public Scrutiny